NETRF Awards Ten Groundbreaking Research Grants to Advance Neuroendocrine Cancer Treatment

BOSTON, M.A., January 29, 2025 - The Neuroendocrine Tumor Research Foundation (NETRF) today announced its newest neuroendocrine cancer research grant recipients. The ten
investigators receiving awards are studying the most promising scientific approaches to understanding and treating neuroendocrine cancer. Funding for these ten grants totals $2
million, bringing NETRF's all-time investment in research to $39.8 million.

"As the largest global funder of neuroendocrine cancer research, NETRF is the lifeline for dedicated scientists working tirelessly to unravel the complexities of this uncommon and
challenging disease," said Elyse Gellerman, NETRF's chief executive officer. "NETRF is making the impossible, possible by accelerating leading-edge research in early detection and
personalized treatments. With this crucial funding, we're not just advancing science-we're paving the way to a future without neuroendocrine cancer," she said.

The new awardees will focus on these themes in neuroendocrine cancer research:
● Discovering the origins of neuroendocrine cancer and causes of disease progression
● Investigating new molecular targets for treatment
● Identifying novel approaches to combat drug resistance to existing treatments
● Studying a novel blood biomarker as a tool for earlier detection
● Improving the safety and effectiveness of alpha-particle radioligand therapy

In this new group of grantees, NETRF is funding six Investigator Awards, two Pilot Awards and two Mentored Research Awards, all focusing on basic and translational science. Six of the 10 awardees are first-time grant recipients of NETRF. The grant recipients are selected through a competitive and rigorous scientific peer-review process. Academic institutions receiving NETRF funding include The University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center at Houston, University of Iowa Health Care, Laval University in Quebec, Massachusetts General Hospital, Korea Military Academy, Dana-Farber Cancer Institute, Stanford University School of Medicine, and UCLA David Geffen School of Medicine. Since its founding in 2005, NETRF has provided funding for 156 research projects at 76 institutions in 17 countries worldwide.

"Our role of building and nurturing the neuroendocrine cancer research community is vital. NETRF is often the sole source of funding for early-career scientists with groundbreaking
ideas," said Todd Gilman, president of NETRF's board of directors. "We're proud that the innovative researchers we've funded are making important discoveries that will have positive impacts on the patient community."

Gellerman thanked the many individuals and foundations whose financial gifts support NETRF's research and education programs, including generous funding from The Carol DeBacker
Charitable Trust, the Martha O'Donnell Pagel Fund for Rare Cancer Research, Karpus Family Foundation, Jim Rodin, Laura and Lew Moorman, and Katherine's Light Foundation.

Neuroendocrine Tumor Research Foundation
31 St. James Avenue, Suite 365
Boston, MA 02116
netrf.org

Lori Dolnick
loridolnick@loridolnick.com

About NETRF
The mission of the Neuroendocrine Tumor Research Foundation (NETRF) is to fund research to discover cures and more effective treatments for neuroendocrine cancers. NETRF is the largest global funder of neuroendocrine cancer research and the preeminent resource for expert patient education and support. NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. Get Involved, Donate, Learn More: Visit www.NETRF.org for more.

This release was published on openPR.